PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Purpose: Obesity promotes pancreatic and breast cancer progression via mechanisms that are poorly understood. Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known. PlGF and its receptor VEGFR-1 have been shown to modulate tumor angiogenesis and promote tumor-associated macrophage (TAM) recruitment and activity. Here, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity. Experimental Design: We established diet-induced obese mouse models of wild-type C57BL/6, VEGFR-1 tyrosine kinase (TK)-null, or PlGF-null mice, and evaluated the role of PlGF/VEGFR-1 signaling in pancreatic and breast cancer mouse models and in human samples. Results: We found that obesity increased TAM infiltration, tumor growth, and metastasis in pancreatic cancers, without affecting vessel density. Ablation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype. Similar findings were observed in a breast cancer model. Obesity was associated with increased systemic PlGF, but not VEGF-A or VEGF-B, in pancreatic and breast cancer patients and in various mouse models of these cancers. Ablation of PlGF phenocopied the effects of VEGFR-1-TK deletion on tumors in obese mice. PlGF/VEGFR-1-TK deletion prevented weight gain in mice fed a high-fat diet, but exacerbated hyperinsulinemia. Addition of metformin not only normalized insulin levels but also enhanced antitumor immunity. Conclusions: Targeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression. Clin Cancer Res; 22(12); 2993–3004. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“Ablation of VEGFR-1 signaling prevents obesity-induced tumor progression without affecting blood vessels of recruitment of immune cells Immunosuppressive (M2-like) TAMs have been shown to promote tumor progression (29).”
BackgroundChan, D. S. M., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., Navarro Rosenblatt, D., Thune, I., Vieira, R., & Norat, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu042 · Cited by 1,165
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“Similar to what was observed in our previous study with anti-VEGFR2 antibody (35), the increased vessel perfusion in the combination groupwas associated with increased recruitment of cytotoxic CD8þ T cells (trend for NK cells; Fig.”
ResultSelf-citationMauer, J., Chaurasia, B., Goldau, J., Vogt, M. C., Ruud, J., Nguyen, K. D., Theurich, S., Hausen, A. C., Schmitz, J., Brönneke, H. S., et al. (2014) · Nature Immunology · doi:10.1038/ni.2865 · Cited by 727 · cited 1×
“However, the shift to M1 macrophages and M1 cytokine profile with VEGFR-1TK deletion is known to be associated with insulin resistance (50) and promote adipocyte cell death (51), which could explain the impaired glucose metabolism, increased levels of insulin and reduced weight gain in Flt1 and Plgf obese mice compare…”
ResultRolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 1×
“Rolny and colleagues reported anM1 shift in TAM polarization after inhibition of PlGF in a nonobese setting (38).”
BackgroundSelf-citationMetformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Tam, J., Duda, D. G., Perentes, J. Y., Quadri, R. S., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004974 · Cited by 99 · cited 1×
“This is consistent with previous findings fromLijnen and colleagues in PlGF-deficient mice (20), although previous work with pharmacologic inhibition of PlGF or VEGFR-1 did not demonstrate the metabolic derangement observed here (20, 49).”
ResultSelf-citation
Cited by
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationIncio, J., Liu, H., Suboj, P., Chin, S. M., Chen, I. X., Pinter, M., Ng, M. R., Nia, H. T., Grahovac, J., Kao, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1177 · Cited by 456
Self-citationButti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 390
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
Munn, L. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1370 · Cited by 257
Metadata
- Authors
- Incio, J., Tam, J., Rahbari, N. N., Suboj, P., McManus, D. T., Chin, S. M., Vardam, T. D., Batista, A., Babykutty, S., Jung, K., Khachatryan, A., Hato, T., Ligibel, J. A., Krop, I. E., Puchner, S. B., Schlett, C. L., Hoffmman, U., Ancukiewicz, M., Shibuya, M., Carmeliet, P., Soares, R., Duda, D. G., Jain, R. K., & Fukumura, D.
- Venue
- Clinical Cancer Research
- Published
- 2016-06-14
- Volume
- 22
- Issue
- 12
- Pages
- 2993-3004
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2276765336
- Cited by
- 134
- References
- 10
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1839
- The paper
- Incio, J., Tam, J., Rahbari, N. N., Suboj, P., McManus, D. T., Chin, S. M., Vardam, T. D., Batista, A., Babykutty, S., Jung, K., Khachatryan, A., Hato, T., Ligibel, J. A., Krop, I. E., Puchner, S. B., Schlett, C. L., Hoffmman, U., Ancukiewicz, M., Shibuya, M., . . . Fukumura, D. (2016). PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.